We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+2.09%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.09B
AUM Growth
-$133M
Cap. Flow
+$26.4M
Cap. Flow %
0.52%
Top 10 Hldgs %
35.29%
Holding
140
New
25
Increased
26
Reduced
29
Closed
16

Top Buys

Rank Stock Value
1
ELVN icon
Enliven Therapeutics
ELVN
+$161M
2
BIIB icon
Biogen
BIIB
+$68.3M
3
BAX icon
Baxter International
BAX
+$66.2M
4
LLY icon
Eli Lilly
LLY
+$62.7M
5
APLS
Apellis Pharmaceuticals
APLS
+$52.5M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$117M
2
PFE icon
Pfizer
PFE
+$71.4M
3
UNH icon
UnitedHealth
UNH
+$50.4M
4
NTRA icon
Natera
NTRA
+$46.7M
5
ETNB
89bio
ETNB
+$46.6M

Sector Composition

Rank Sector Weight
1 Healthcare 96.7%
2 Industrials 0.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APLS
26
DELISTED
Apellis Pharmaceuticals
APLS
$60M 1.18%
+910,200
New +$52.5M
SIBN icon
27
SI-BONE Inc
SIBN
$809M
$57.4M 1.13%
2,919,454
-448,546
-13% -$7.97M
PRLD icon
28
Prelude Therapeutics
PRLD
$364M
$57.2M 1.12%
10,039,691
– –
SPRY icon
29
ARS Pharmaceuticals
SPRY
$552M
$56.9M 1.12%
8,740,887
– –
VRTX icon
30
Vertex Pharmaceuticals
VRTX
$124B
$56M 1.1%
177,600
-93,900
-35% -$28.2M
NTRA icon
31
Natera
NTRA
$35.8B
$54.1M 1.06%
973,581
-972,772
-50% -$46.7M
EW icon
32
Edwards Lifesciences
EW
$49.3B
$52.1M 1.02%
630,000
-230,500
-27% -$18.1M
SCPH
33
DELISTED
scPharmaceuticals
SCPH
$50.4M 0.99%
5,559,528
– –
NBIX icon
34
Neurocrine Biosciences
NBIX
$18.2B
$49.5M 0.97%
489,000
-198,700
-29% -$20.7M
IRON icon
35
Disc Medicine
IRON
$2.8B
$48.1M 0.94%
2,269,637
+108,696
+5% +$2.42M
KDNY
36
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$47M 0.92%
2,029,300
– –
XTNT icon
37
Xtant Medical Holdings
XTNT
$59.1M
$46.6M 0.92%
73,114,592
– –
VECT
38
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
$43.9M 0.86%
5,156,561
-1,850,300
-26% -$15.3M
ACET icon
39
Adicet Bio
ACET
$76M
$42.9M 0.84%
465,446
– –
QURE icon
40
uniQure
QURE
$2.74B
$41.6M 0.82%
2,064,455
+316,900
+18% +$6.65M
XENE icon
41
Xenon Pharmaceuticals
XENE
$6.16B
$41.1M 0.81%
1,149,100
– –
TVTX icon
42
Travere Therapeutics
TVTX
$5.13B
$39.2M 0.77%
1,744,300
+491,170
+39% +$10.4M
MRSN
43
DELISTED
Mersana Therapeutics
MRSN
$37M 0.73%
360,457
– –
BLU
44
DELISTED
BELLUS Health Inc.
BLU
$36.8M 0.72%
5,108,900
+400,000
+8% +$3.1M
SNDX icon
45
Syndax Pharmaceuticals
SNDX
$1.68B
$36.2M 0.71%
1,711,675
-294,825
-15% -$7.33M
JANX icon
46
Janux Therapeutics
JANX
$900M
$34.3M 0.67%
2,836,386
– –
MRTX
47
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$34M 0.67%
913,650
-370,042
-29% -$16.6M
PGNY icon
48
Progyny
PGNY
$2.46B
$33.3M 0.65%
1,037,912
+2,912
+0.3% +$96.2K
RPTX
49
DELISTED
Repare Therapeutics
RPTX
$32.7M 0.64%
3,322,488
– –
TELA icon
50
TELA Bio
TELA
$30.9M
$32.2M 0.63%
3,027,542
– –
1
2
3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q1 2023 Portfolio in Review

As of Q1 2023, OrbiMed held 140 positions worth $5.09B, down 2.6% from $5.23B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

OrbiMed's Q1 2023 filing shows 25 new, 26 increased, 29 reduced and 16 closed positions. Its largest new stake was Baxter International: 1,562,000 shares worth $63.4M. The largest sale was Seagen Inc. Common Stock, an estimated $117M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Industrials.

  • OrbiMed's largest Q1 2023 buy was Baxter International: 1,562,000 shares worth $63.4M.
  • OrbiMed added most to Enliven Therapeutics in Q1 2023, an estimated $161M increase.
  • OrbiMed's biggest Q1 2023 reduction was UnitedHealth, cutting an estimated $50.4M.
  • OrbiMed fully exited Seagen Inc. Common Stock in Q1 2023, selling an estimated $117M.
  • OrbiMed's ten largest holdings make up 35% of its $5.09B portfolio in Q1 2023.
  • OrbiMed opened 25 new positions and closed 16 in Q1 2023.
  • OrbiMed's portfolio value fell 2.6% quarter-over-quarter to $5.09B.

Based on OrbiMed's 13F filing for Q1 2023, filed 15 May 2023.